Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Keros Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $29.7 million for Q4 2025.

• Quarterly Operating Expenses fell 47.32% year-over-year to $29.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $176.5 million (down 17.67% YoY) and the FY2025 annual result came in at $176.5 million, down 17.67% from the prior year.
• Operating Expenses was $29.7 million for Q4 2025 at Keros Therapeutics, roughly flat from $29.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $59.2 million in Q1 2025 and bottomed at $15.6 million in Q2 2021.
• A 5-year average of $37.6 million and a median of $35.4 million in 2022 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 96.46% — and 2025, when it sank 49.79%.
• Keros Therapeutics' Operating Expenses stood at $24.9 million in 2021, then grew by 28.53% to $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then gained by 20.81% to $56.3 million in 2024, then slumped by 47.32% to $29.7 million in 2025.
• Business Quant data shows KROS's Operating Expenses at $29.7 million in Q4 2025, $29.6 million in Q3 2025, and $58.0 million in Q2 2025.